+ Evidence in focus Publication summary: Ananian CE, et al. Adv Wound Care (New Rochelle) (2019)*

Smith-Nephew

Addition of GRAFIX PL PRIME[°] Lyopreserved Placental Membrane to standard of care (SoC) increased the number of chronic wounds achieving complete closure compared with SoC alone



59.2% complete wound closure



Overview

- Open-label, retrospective case series across five centers in the USA
- Patients (N=78) had 98 non-healing wounds (mean duration, 8.7 months; mean size, 13.3cm²), defined as wounds with no progression towards closure with 4 weeks of SoC or in patients with significant comorbidities that increase risk of nonclosure
- Of these, there were 41 diabetic foot ulcers (DFUs), 19 venous leg ulcers (VLUs), 10 surgical wounds and 28 others (eg, pressure ulcers and arterial wounds)
- Patients received GRAFIX PL PRIME Membrane, with up to 12 weekly applications, plus SoC including wound cleaning and debriding as appropriate, and non-adherent dressings



- With GRAFIX PL PRIME Membrane plus SoC, 59.2% of wounds achieved complete closure in a median of 63 days (6 applications)
 - Rates were similar for the various wound types (Figure)
- Of wounds that did not achieve complete closure, the mean percentage area reduction was 42.3%
- More wounds of ≤12 months in duration closed than those of >1 year in duration (65.8 vs 30.0%; p=0.004)
 - Median time to closure was shorter for wounds of ≤12 months. duration than those >1 year (62.5 vs 119.5 days; p=0.01)



Figure. Complete wound closure (%) across the wound types managed with GRAFIX PL PRIME Membrane plus SoC

Conclusions

Citation

*Ananian CE, Davis DR, Johnson EL, et αl. Wound closure outcomes suggest clinical equivalency between lyopreserved and cryopreserved placental membranes containing viable cells. Adv Wound Care (New Rochelle). 2019;8(11):546-554.

Available from: Advanced Wound Care (New Rochelle)

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Study sponsored by Osiris Therapeutics Inc, which is now a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. Advanced Wound Management, Smith & Nephew, Inc. Fort Worth, TX 76109 USA | GRAFIX Customer Care Center: T 888-674-9551 F 443-283-4419 | OSiris, GRAFIX, GRAFIXPL, GRAFIX PRIME, GRAFIX CORE, GRAFIX XC, and GRAFIXPL PRIME are trademarks of Osiris Therapeutics, Inc., a wholly owned direct subsidiary of Smith & Nephew Consolidated, Inc. | ©2022 Smith & Nephew, Inc. | GRCE48-34990-1022 www.smith-nephew.com www.osiris.com